-5%
Imeglimin acts through a dual mechanism:
Amplification of glucose-stimulated insulin secretion (GSIS):
- Preserves pancreatic β-cell mass, enhancing insulin production.
- Supports glucose-stimulated ATP generation and increases NAD+ synthesis in β-cells.
Enhanced insulin action:
- Reduces hepatic glucose production and improves insulin signaling in the liver and skeletal muscle.
At the molecular level, Imeglimin addresses mitochondrial dysfunction—a critical factor in type 2 diabetes (T2D) pathogenesis. Its effects include:
- Rebalancing respiratory chain activity to reduce oxidative stress.
- Preventing mitochondrial permeability transition pore opening, reducing cell death.
Imeglimin’s unique mechanism targets defective cellular energy metabolism, differentiating it from other major anti-diabetic classes like biguanides, sulfonylureas, and GLP-1 receptor agonists.
Imeglimin is indicated for the treatment of type 2 diabetes mellitus (T2D):
- Effective as monotherapy or in combination with other diabetes therapies.
- Demonstrated safety and promising efficacy in clinical studies.
